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Background: Most cases of acute leukemia arise without identifiable risk factors. Studies 
investigating the impact of autoimmune diseases and infections on leukemogenesis have 
revealed conflicting results. If inflammation increases the risk of acute myeloid leukemia 
(AML),  nonsteroidal anti-inflammatory drug (NSAID) use may decrease the risk of leukemia.
Methods: We conducted a case-control study of 3,053 patients with AML diagnosed between 
2000 and 2013, who were registered in the Danish National Acute Leukemia Registry, and 30,530 
population controls matched on sex and age. We identified prescriptions through the Danish 
National Health Service Prescription Database. We used conditional logistic regression analysis to 
compute ORs associating AML with NSAID use overall, in patients with inflammatory diseases, 
and for specific AML subtypes (de novo AML, AML related to previous hematological disease, ie, 
secondary AML [sAML], or therapy-related AML [tAML; exposed to previous cytotoxic therapy]).
Results: Overall, NSAID use was not associated with a lower risk of AML (OR 1.1, 95% CI=1.0–
1.2), de novo AML (OR 1.0, 95% CI=0.9–1.1), and sAML/tAML (OR 1.3, 95% CI=1.1–1.5). In 
addition, in patients with known inflammatory diseases, NSAIDs did not affect AML risk (OR 0.9, 
95% CI=0.5–1.6). Number of prescriptions, type of NSAID, age, or sex did not influence the results.
Conclusion: In line with our recent findings that showed no association between autoimmune 
diseases and infections and de novo AML, NSAID use was not found to reduce the risk of AML.
Keywords: acute myeloid leukemia, population controls, population-based, risk, NSAIDs, 
inflammation
Introduction
The most important risk factors for acute myeloid leukemia (AML) are prior cytotoxic 
therapy (therapy-related AML [tAML]) and/or antecedent hematological diseases 
(secondary AML [sAML]).1 Still, most cases arise without identifiable risk factors 
(de novo AML). Studies have found an association between infections,2–5 autoimmune 
diseases,2,6 and AML, suggesting that acute and chronic inflammation may influence 
leukemogenesis. We recently demonstrated that, in general, this association is confined 
to tAML and sAML.7
It is well accepted that inflammation plays a carcinogenic role in lymphomas and 
solid cancers.8 In line with this, nonsteroidal anti-inflammatory drugs (NSAIDs) 
have been shown to reduce the risk of cancers such as colon cancer, likely due to 
prostaglandins and Cox-2 inhibition of the Wnt signaling pathway, a protein signal 
transduction pathway demonstrated to play an important role in cell regeneration 
and carcinogenesis.9
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Furthermore, the Wnt pathway affects nonmalignant 
proliferation of the bone marrow, and aberrant activation of 
Wnt signaling involving genes implicated in leukemogenesis 
has been demonstrated in AML (eg, AML1-ETO and mutated 
FLT3).10–12 If inflammation plays an important role in the 
development of AML (in particular sAML and tAML), it 
is important to determine if use of anti-inflammatory drugs 
reduces the risk of AML.
Limited studies have investigated the effects of NSAID 
use in AML patients. Ross et al found a chemo-preventive 
effect of regular- to extra-strength doses of aspirin on AML 
in only women; however, no effects of ibuprofen and Cox-2 
inhibitors were shown.13 Consistent with this finding, Kasum 
et al found a reduced risk of AML in aspirin users in a cohort 
of older women,14 whereas Pogada et al demonstrated that 
long-term use of NSAID reduces the overall risk of AML.15 
Small study samples, selected patients, and use of self-
reported data limit previous reports. In a larger study using 
prescription data, Bhayat et al did not find any association 
between AML and use of NSAIDs.16 However, the AML diag-
noses were not validated, no clinical information was avail-
able, and results were only given for unspecified NSAIDs, 
which may be important in light of previous findings.
To further investigate whether NSAID use reduces the 
risk of AML, we designed a national population-based case-
control study among all Danish AML patients diagnosed 
between 2000 and 2013 and matching population controls. We 
stratified results by NSAID subtypes, sex, age, inflammatory 
disease, and by whether AML developed de novo or follow-
ing antecedent hematological diseases or cytotoxic therapy.
Methods
The source population for this case-control study was Danish 
residents ≥15 years of age (Danish population 5.7 million)17 
observed between 2000 and 2013. All Danish residents are 
provided with tax-supported medical care, including deduc-
tion on prescription medication.
aMl cases
We included all nonpromyelocytic AML cases 16 years or 
older diagnosed in Denmark between January 1, 2000, and 
December 31, 2013, identified through the Danish National 
Acute Leukemia Registry, which has been described in 
details elsewhere.18,19 We included information on date of 
diagnosis as well as data on AML type (de novo, sAML, 
and tAML).20 The definition was based on the WHO clas-
sification system and was based on information on prior 
exposure to chemotherapy or radiotherapy for an unrelated 
disease (tAML), and/or preceding myeloid hematological 
malignancy (sAML; eg, myelodysplastic syndrome and 
myeloproliferative neoplasms).21 From the Danish National 
Registry of Patients (DNRP), we retrieved information on 
autoimmune diseases and five chronic autoimmune inflam-
matory disease categories were elected to retrieve the patient’s 
information (Table S1).
selection of population controls
The Civil Registration System22 and the DNRP23 were used 
to select 10 controls for each AML case. Controls had to 
be alive at the index date (day of AML diagnosis of their 
matched patient) and without a history of AML (ICD-10: 
DC 92.0–92.9, ICD-8: 205.0 registered in the DNRP). Risk 
set sampling24 was used to match controls with cases on sex 
and date of birth.
Use of nsaiD
We obtained data on NSAID prescriptions through the 
 Danish National Health Service Prescription Database.25 The 
database is maintained by the Danish Medicines Agency and 
includes information on all prescribed drugs dispensed from 
Danish pharmacies. Information includes the unique civil 
registration number, date of prescription, and type of drug 
prescribed according to the Anatomical Therapeutic Chemi-
cal (ATC) classification system. We used ATC codes included 
in the M01A category comprising systemic  nonsteroidal 
anti-inflammatory and antirheumatic products to identify 
prescriptions for NSAIDs. We categorized NSAIDs into 
nonselective NSAIDs, Cox-2 inhibitors, and others (specific 
ATC codes used to define NSAID subgroups; Table S2, online 
only). Only higher priced small packages of low-dose (20 
pills, 200 mg) ibuprofen can be bought over the counter, 
and therefore, long-time users are likely to redeem prescrip-
tions.26 Prescription data are only available after 1995, which 
allowed for a minimum 5-year opportunity for exposure to 
NSAIDs before AML diagnosis. We excluded prescriptions 
<3 years prior to AML diagnosis to minimize the risk of 
reverse causality and detection bias. In the overall and NSAID 
subgroup analysis, we defined NSAID use as more than one 
prescription redeemed.
statistical analysis
We computed the frequencies and proportions of cases and 
controls by categories of drug exposure and covariates.
We used conditional logistic regression analysis to esti-
mate the ORs associating AML with NSAID use. Given the 
density sampling of controls, ORs in conditional logistic 
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regression are valid estimates of the corresponding incidence 
rate ratios.
All results were given for NSAID overall, by subgroups 
(nonselective, Cox-2, and other NSAIDs), and by number of 
NSAID prescriptions (0, 1–2, 3–5, 6–10, >10). All results 
were given overall and stratified by sex, age (<60 years, ≥60 
years), type of AML (de novo, sAML, or tAML), and in 
patients with known inflammatory diseases (connective tis-
sue disease; ICD-10). Results were provided with 95% CIs.
We repeated all analyses using 1-year exclusion of pre-
scription history. In addition, we repeated the overall analysis 
using >1 redeemed prescription as exposure.
Analyses were performed using SAS, version 9.4 (SAS 
Institute Inc., Cary, NC, USA). The study protocol was 
approved by the Danish Data Protection Agency (jr. nr. 
2013-41-1570).
Results
The final study population included 3,053 AML cases and 
30,530 sex- and age-matched population controls. The median 
age was 69.4 years (15–99). The prevalence of AML was sta-
ble during the study period with 73.6% de novo AML, 19.8% 
sAML, and 6.7% tAML. Fifty-five percent of the patients 
were men. Descriptive characteristics are shown in Table 1.
 The number of patients and controls redeeming a pre-
scription for NSAID during the years 1995 and 3 years prior 
to their AML diagnosis by number of prescriptions are shown 
in Table 1. 
The number of AML patients who redeemed >1 prescrip-
tion (not accounting patients who only redeemed prescrip-
tions <1 year before the AML diagnosis) was 2,079 (68.1%). 
Among the 30,530 controls, 20,139 (66.0%) had redeemed 
at least 1 NSAID prescription during the years 1995–2013 
and >1 year before their index date. Ignoring prescriptions <3 
years before AML diagnosis or index date, the numbers were 
1,869 (61.2%) for cases and 18,128 (59.4%) for controls.
The associations between NSAID use and risk of AML 
are shown in Table 2.
Overall, any use of NSAID prior to AML diagnosis was 
not associated with the risk of AML (OR 1.1, 95% CI=1.0–
1.2). Similar results were seen across NSAID  subtypes. In 
addition, long-term use did not reduce the risk of AML when 
the risk of AML was compared between patients with dif-
ferent numbers of prescriptions (1–2 prescriptions, OR 1.0, 
95% CI=0.9–1.1) vs those with >10 prescriptions (OR 1.1, 
95% CI=0.9–1.2).
When repeating the analysis for patients with de novo 
AML and sAML/tAML separately (Table 2), an increased 
risk of AML in NSAID users across NSAID subtypes and 
numbers of prescriptions was observed in patients with 
sAML/tAML (OR 1.3, 95% CI=1.1–1.5), whereas use of 
NSAIDs was not associated with the risk of de novo AML 
(OR 1.0, 95% CI=0.9–1.1). Stratification by sex or age (<60 
vs ≥60 years) did not change the interpretation of results, 
although lower estimates were found in women without any 
evidence of protective effect (Table 3).
Restricting analysis to patients with known inflammatory 
conditions measured as autoimmune diseases, NSAID con-
sumption did not reduce the overall risk of AML (Table 4). 
In a subgroup analysis, NSAID use did not affect the risk of 
AML in patients with connective tissue disease (OR 0.9, 95% 
CI=0.5–1.6) compared with non-NSAID users. In contrast, 
we did observe a lower risk of AML in patients with inflam-
matory gastrointestinal conditions; however, results were 
imprecise (OR 0.6, 95% CI=0.2–1.2).
To test the robustness of our results, we repeated all analy-
ses ignoring prescriptions only 1 year before AML diagnosis 
or index date (results not shown). In general, the estimates 
were slightly higher when using only 1 year as an exclusion 
criterion (NSAID overall: 1 year: OR 1.0, 95% CI=0.9–1.1 
vs 3 years: OR 1.1, 95 CI=1.0–1.2). Thus, our overall conclu-
sions did not change based on these results. In addition, we 
Table 1 Characteristics of patients with aMl and their matched 
population controls in Denmark, 2000–2013
AML cases Population controlsa
N=3,053 % N=30,530 %
sex
Men 1,685 55.2 16,850 55.2
Women 1,368 44.8 13,680 44.8
age, years
Median age, years 
(iQR)
69.4 (58.2–78.2) 69.4 (58.2–78.2)
<59 882 28.9 8,820 28.9
60–74 1,138 37.3 11,380 37.3
≥75 1,033 33.8 10,330 33.8
Prior chemotherapy/hematological disease
De novo aMl 2,247 73.6
saMl 603 19.8
taMl 203 6.7
no. of nsaiD prescriptionsb
≤2 759 24.9 7,962 26.1
3–5 460 15.1 4,573 15.0
6–10 360 11.8 3,066 10.0
>10 500 16.4 4,538 14.9
Notes: aCases and controls were matched on date of birth and sex. bDuring the 
calendar year before diagnosis among aMl cases or the year before the index date 
among controls.
Abbreviations: aMl, acute myeloid leukemia; iQR, interquartile range; saMl, 
secondary AML; tAML, therapy-related AML; NSAID, nonsteroidal anti-inflammatory 
drug.
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repeated analysis defining NSAID users as subjects with 1 or 
more prescriptions. This did not change the estimates of the 
overall analysis  (> 1 prescription: OR 1.1, 95% CI= 1.0–1.2 
vs ≥ 1 prescription: OR 1.1, 95% CI= 1.0–1.2).
Discussion
In this large population-based case-control study, we demon-
strated that NSAID use does not protect against AML overall 
or in patients with known inflammatory conditions.
Prior studies have attempted to define the effect of NSAID 
use on the risk of leukemogenesis, and conflicting results 
have been reported. For example, in women, a protective 
effect of nonaspirin anti-inflammatory agents (OR 0.5, 95% 
CI=0.2–0.9) and that of general NSAID use for more than 
4 weeks have been reported in different studies.13,15 These 
results are in clear contrast to our observations  showing 
Table 2 ORs for aMl according to nsaiD use in 3,053 aMl cases and 30,530 population controls in Denmark, 2000–2013a
NSAID prescriptions No. of cases (%) No. of controls (%) ORb (95% CI)
Type of nsaiD
nsaiDs 1,869 (61.2) 18,128 (59.4) 1.1 (1.0–1.2)
nonselective nsaiDs 1,606 (52.6) 15,553 (50.9) 1.1 (1.0–1.2)
Cox-2 inhibitors 221 (7.2) 2,052 (6.7) 1.1 (0.9–1.3)
Other nsaiDs 789 (25.8) 7,678 (25.1) 1.0 (1.0–1.1)
no. of prescriptions, all nsaiDs
1–2 prescriptions 771 (25.3) 7,878 (25.8) 1.0 (0.9–1.1)
3–5 prescriptions 414 (13.6) 4,101 (13.4) 1.0 (0.9–1.1)
6–10 prescriptions 313 (10.3) 2,052 (8.5) 1.2 (1.1–1.4)
>10 prescriptions 371 (12.2) 3,557 (11.7) 1.1 (0.9–1.2)
Type of aMl
De novo
Type of nsaiD
nsaiDs 1,336 (59.5) 13,206 (58.8) 1.0 (0.9–1.1)
nonselective nsaiDs 1,143 (50.9) 11,328 (50.4) 1.0 (0.9–1.1)
Cox-2 inhibitors 155 (6.9) 1,479 (6.6) 1.1 (0.9–1.3)
Other nsaiDs 557 (24.8) 5,521 (24.6) 1.0 (0.9–1.1)
no. of prescriptions, all nsaiDs
1–2 prescriptions 579 (25.8) 5,813 (25.9) 1.0 (0.9–1.1)
3–5 prescriptions 274 (12.2) 3,001 (13.4) 0.9 (0.8–1.0)
6–10 prescriptions 215 (9.6) 1,812 (8.1) 1.2 (1.0–1.4)
>10 prescriptions 268 (11.9) 2,580 (11.5) 1.1 (0.9–1.2)
saMl or taMl
Type of nsaiD
nsaiDs 533 (66.1) 4,922 (61.1) 1.3 (1.1–1.5)
nonselective nsaiDs 463 (57.4) 4,225 (52.4) 1.2 (1.1–1.5)
Cox-2 inhibitors 66 (8.2) 573 (7.1) 1.2 (0.9–1.5)
Other nsaiDs 232 (28.8) 2,157 (26.8) 1.1 (0.9–1.3)
no. of prescriptions, all nsaiDs
1–2 prescriptions 192 (23.8) 2,065 (25.6) 0.9 (0.8–1.1)
3–5 prescriptions 140 (17.4) 1,100 (13.6) 1.3 (1.1–1.6)
6–10 prescriptions 98 (12.2) 780 (9.7) 1.3 (1.0–1.6)
>10 prescriptions 103 (12.8) 977 (12.1) 1.1 (0.9–1.3)
Notes: aPrescriptions were recorded from 1995 through 3 calendar years before the date of aMl diagnosis. bConditional on date of birth and sex.
Abbreviations: AML, acute myeloid leukemia; NSAID, nonsteroidal anti-inflammatory drug; sAML, secondary AML; tAML, therapy-related AML.
a lack of  protective or dose–response effect of NSAIDs 
on leukemogenesis. However, our findings resemble those 
from 2 separate reports that failed to demonstrate any pro-
tective effect of NSAID use on AML risk.14,16 Significant 
methodological concerns were observed in previous stud-
ies, including small cohorts (28–568 cases) and reliance on 
self-reported data in all but 1 prior report.13–15 Thus, study 
participants were required to recall medicine intake for up 
to 10 years and differentiate between different subtypes of 
NSAIDs. In addition, some studies used proxy responders, 
which is likely to further increase the risk of recall bias. 
Participation rates were low (42%–58%), increasing the risk 
of selection bias and favoring long-term survivors reducing 
the generalizability.
Overall, our study did not find NSAID to be associated 
with an increased risk of AML. Patients with sAML and 
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tAML may have a higher consumption of anti-inflammatory 
drugs and an increased risk of AML mediated through the 
premalignant disorders or cytotoxic therapy, suggesting 
against a causal relationship between NSAID use and AML. 
Our results stratified by type of AML support this theory, as 
Table 3 ORs for aMl according to nsaiD use by sex and age in 3,053 aMl cases and 30,530 population controls in Denmark, 2000–2013a
NSAID prescriptions No. of cases (%) No. of controls (%) ORb (95% CI)
sex
Women
Type of nsaiD
nsaiDs 866 (63.3) 8,549 (62.5) 1.0 (0.9–1.2)
nonselective nsaiDs 731 (53.4) 7,299 (53.)4 1.0 (0.9–1.1)
Cox-2 inhibitors 118 (8.6) 1,159 (8.5) 1.0 (0.8–1.3)
Other nsaiDs 408 (29.8) 3,903(28.5) 1.1 (0.9–1.2)
no. of prescriptions, all nsaiDs
1–2 prescriptions 341 (24.9) 3,534 (25.8) 1.0 (0.8–1.1)
3–5 prescriptions 187 (13.7) 1,872 (13.7) 1.0 (0.9–1.2)
6–10 prescriptions 141 (10.3) 1,272 (9.3) 1.1 (0.9–1.4)
>10 prescriptions 197 (14.4) 1,871 (13.7) 1.1 (0.9–1.3)
Men
Overall
Type of nsaiD
nsaiDs 1,003 (59.5) 9,579 (56.8) 1.1 (1.0–1.3)
nonselective nsaiDs 875 (51.9) 8,254 (49.0) 1.1 (1.0–1.3)
Cox-2 inhibitors 103 (6.1) 893 (5.3) 1.2 (0.9–1.5)
Other nsaiDs 381 (22.6) 3,775 (22.4) 1.0 (0.9–1.2)
no. of prescriptions, all nsaiDs
1–2 prescriptions 430 (25.5) 4,344 (25.8) 1.0 (0.9–1.1)
3–5 prescriptions 227 (13.5) 2,229 (13.2) 1.0 (0.9–1.2)
6–10 prescriptions 172 (10.2) 1,320 (7.8) 1.4 (1.1–1.6)
>10 prescriptions 174 (10.3) 1,686 (10.0) 1.0 (0.9–1.3)
age
<60 years
Type of nsaiD
nsaiDs 487 (55.2) 4,783 (54.2) 1.1 (0.9–1.2)
nonselective nsaiDs 443 (50.2) 4,310 (48.9) 1.1 (0.9–1.2)
Cox-2 inhibitors 23 (2.6) 269 (3.0) 0.9 (0.6–1.3)
Other nsaiDs 155 (17.6) 1,534 (17.4) 1.0 (0.8–1.2)
no. of prescriptions, all nsaiDs
1–2 prescriptions 240 (27.2) 2,592 (29.4) 0.9 (0.8–1.1)
3–5 prescriptions 114 (12.9) 1,133 (12.8) 1.0 (0.8–1.2)
6–10 prescriptions 80 (9.1) 550 (6.2) 1.5 (1.2–2.0)
>10 prescriptions 53 (6.0) 508 (5.8) 1.1 (0.8–1.4)
≥60 years
Type of nsaiD
nsaiDs 1,382 (63.7) 13,345 (61.5) 1.1 (1.0–1.2)
nonselective nsaiDs 1,163 (53.6) 11,243 (51.8) 1.1 (1.0–1.2)
Cox-2 inhibitors 198 (9.1) 1,783 (8.2) 1.1 (1.0–1.3)
Other nsaiDs 634 (29.2) 6,144 (28.3) 1.1 (1.0–1.2)
no. of prescriptions, all nsaiDs
1–2 prescriptions 531 (24.5) 5,286 (24.3) 1.0 (0.9–1.1)
3–5 prescriptions 300 (13.8) 2,968 (13.7) 1.0 (0.9–1.2)
6–10 prescriptions 233 (10.7) 2,042 (9.4) 1.2 (1.0–1.3)
>10 prescriptions 318 (14.6) 3,049 (14.0) 1.1 (0.9–1.2)
Notes: aPrescriptions were recorded from 1995 through 3 calendar years before the date of aMl diagnosis. bConditional on date of birth and sex.
Abbreviations: AML, acute myeloid leukemia; NSAID, nonsteroidal anti-inflammatory drug.
the association between NSAID use and high risk of AML 
was only seen for sAML/tAML patients, whereas a clear null 
result was seen for de novo AML.
Although the literature on whether NSAIDs reduce AML 
risk is sparse, studies have found an association between 
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autoimmune diseases, infections, and AML.2–4,6 However, 
study designs and lack of clinical data prevented investigation 
of whether inflammation or bias could explain their findings. 
The finding that NSAID overall did not reduce the risk of 
AML supports our hypothesis that at least for de novo AML, 
inflammation is unlikely to be responsible for initiation of 
leukemogenesis7 but may be associated with progression to 
AML in patients with an underlying condition such as  prior 
hematological disorder or selection of Clonal Hematopoiesis 
of Indeterminate Potential following cytotoxic therapy. 
In patients with known inflammatory disease, patients are 
likely to consume NSAIDs at higher doses and longer periods 
of time. In patients with connective tissue disease such as 
rheumatoid arthritis, use of NSAIDs did not influence the 
risk of AML. Interestingly, though results were imprecise, 
we did observe a lower risk of AML in NSAID users with 
gastrointestinal inflammatory conditions. In line with this, we 
recently found an association between both gastrointestinal 
infections and gastrointestinal autoimmune conditions and 
risk of AML, suggesting that inflammation in the gastroin-
testinal tracts causes immune-related/inflammation-driven 
leukemogenesis. Therapeutic immune-modulating agents (eg, 
azathioprine) increase both risk of infections and AML and 
may explain prior findings. However, the observed tendency 
toward a lower AML risk in patients with gastrointestinal 
inflammatory disease with NSAID consumption calls for 
further investigation of the potential role of gastrointestinal 
inflammation in leukemogenesis.
To our knowledge, this is the largest study investigating 
the association between NSAID use and risk of AML. The 
national population-based design and the use of matched pop-
ulation-based controls reduce selection bias and increase the 
generalizability of the study results. The use of prescription 
information prospectively collected of purposes independent 
of the study aims reduces the risk of recall bias. Both AML 
coverage and accuracy of the diagnosis are high (>99%).19 
Furthermore, our findings were consistent across age and sex 
strata, thus strengthening our conclusions.
Table 4 Risk of AML in patients with inflammatory disease and NSAID consumption compared with patients without NSAID 
consumptiona
Inflammatory disease No. of cases (%) No. of controls (%) ORb (95% CI)
endocrine disease 46 (75.4) 438 (67.5) 1.5 (0.8–2.9)
Central nervous system disease 7 (63.6) 50 (62.5) 1.2 (0.3–5.1)
gastrointestinal disease 25 (64.1) 203 (74.6) 0.6 (0.3–1.2)
Connective tissue disease 88 (86.3) 622 (87.7) 0.9 (0.5–1.6)
Vasculitis syndrome 33 (82.5) 222 (79.3) 1.2 (0.5–3.0)
Notes: aConditional on date of birth and sex. bPrescriptions were recorded from 1995 through 3 calendar years before the date of aMl diagnosis.
Abbreviations: AML, acute myeloid leukemia; NSAID, nonsteroidal anti-inflammatory drug.
Our study has a few limitations. It was not known whether 
patients who were prescribed NSAID actually consumed 
these agents as prescribed. Defining NSAID users as persons 
with >1 prescription increased the likelihood that patients 
who redeemed prescriptions actually were NSAID users. In 
addition, adherence is expected to be similar between cases 
and controls. Cases and controls are equally likely to buy 
over-the-counter drugs and since we did not see a protec-
tive effect of patients with higher number of prescription 
and defined NSAID users as persons with >1 prescription, 
this is unlikely to have influenced our results. The multiple 
comparison approach may have resulted in some significant 
associations simply happening by chance, and results of the 
stratified analyses must be interpreted with caution. How-
ever, the analyses were primarily used to test and confirm 
a predefined hypothesis that NSAID use is not associated 
with an increased risk of AML, reducing the likelihood of 
our conclusions relying on coincidence.
Conclusion
In this large population-based study of 3,165 AML cases 
and 31,650 controls, we did not find that NSAID reduces 
the risk of AML. Age, sex, and number of prescriptions did 
not influence the results. In line with our recent findings of 
no association between autoimmune diseases and infections 
and de novo AML, these findings support our hypothesis 
that inflammation plays a minor role in the initiation of de 
novo AML.
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Supplementary material
Table S1 Diagnoses and ICD codes included in 5 chronic autoimmune/inflammatory disease categories
Autoimmune disease categories ICD-8 ICD-10
endocrine diseases
grave’s disease 242.00, 242.01, 242.08, 242.09 e05.0
autoimmune thyroiditis 244.01, 245.03 e06.3
addison’s disease 255.10, 255.11 e27.1a, e27.2a
Diabetes i 249 e10
gastrointestinal/hepato-biliary system diseases
Pernicious anemia 281.00, 281.01, 281.08, 281.09 D51.0
Coeliac disease 269.00 K90.0
Crohn’s disease 563.01, 563.02, 563.09 K50, M07.4
Ulcerative colitis 563.19 K51, M07.5
Primary biliary cirrhosis 571.90 K74.3
skin diseases
Pemphigus/pemphigoid 694.00–694.03, 694.05 l10.0, l10.2, l10.4, l12.0
Dermatitis herpetiformis 693.08, 693.09 l13.0
Psoriasis 696.09, 696.10, 696.19 l40, M07.0-M07.3
Vitiligo 709.01 l80
Rheumatological diseases
scleroderma 734.0 M34
Juvenile rheumatoid arthritis 712.09 M05, M06, M08, g73.7D
Rheumatoid arthritis 712.19, 712.29, 712.39, 712.59 i32.8a, i39.8e, i41.8a, i52.8a
ankylosing spondylitis 712.49 M45
Polymyositis/dermatomyositis 716.09, 716.19 M33
systemic lupus erythematosus 734.19 M32, g73.7C, i39.8C, n08.5a, n16.4B
sjögren’s syndrome 734.90 M35, g73.7a, n16.4a
sarcoidosis 135.99 D86, g53.2, h22.1a, i41.8B, K77.8B, M63.3
Vasculitis syndromes
Polyarteritis nodosa 446.09 M30.0
Wegener’s granulomatosis 446.29 M31.3
Temporal arteritis/polymyalgia rheumatica 446.30, 446.31, 446.39 M31.5, M31.6, M35.3
Abbreviation: ICD, International Classification of Diseases.
Table S2 aTC coding used to identify nsaiD prescriptions in the Danish national health service Prescription Database
Type of NSAIDs ATC code
non-selective nsaiDs
Diclofenac M01aB05
ibuprofen M01ae01
naproxen M01ae02
Cox-2 inhibitors
Celecoxib M01ah01
Rofecoxib M01ah02
Others
Phenylbutazone, indomethacin, sulindac, tolmetin M01aa01, M01aB01
etodolac, aceclofenac, piroxicam, tenoxicam M01aB02, M01aB03, M01aB08, M01aB16, M01aC01,
lornoxicam, meloxicam, ketoprofen, fenoprofen M01aC02, M01aC05, M01aC06, M01ae03, M01ae04,
Flurbiprofen, tiaprofenic acid, dexibuprofen M01ae09, M01ae11, M01ae14, M01ae17,
Dexketoprofen, etoricoxib, nabumetone M01ah05, M01aX01
Abbreviations: ATC, Anatomical Therapeutic Chemical; NSAID, nonsteroidal anti-inflammatory drug.
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